SmarTrend Watching for Potential Rebound in Shares of Illumina After 3.13% Loss
Comtex SmarTrend(R) - Tue Dec 23, 4:27PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $182.88 to a high of $189.99. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $183.14 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 186.22 (+2.72)
Illumina Falls 3.13% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Dec 23, 4:26PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $182.88 to a high of $189.99. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $183.14 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 186.22 (+2.72)
J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015
at The Street - Mon Dec 22, 7:23AM CST
Which biotech and pharmaceuticals stocks should investors buy in 2015? JPMorgan named six companies with the best investment cases as part of its top U.S. stocks picks for 2015.
VRX: 140.33 (-0.22), BMRN: 88.18 (+0.89), JAZZ: 165.33 (+1.83), ALXN: 181.96 (+3.09), ILMN: 186.22 (+2.72), BMY: 59.15 (-0.01)
Illumina to Webcast Live Presentation at the J.P. Morgan Annual Healthcare Conference
Business Wire - Mon Dec 22, 5:30AM CST
Illumina, Inc. (NASDAQ:ILMN) today announced that it will webcast the Company's presentation at the J.P. Morgan 33rd Annual Healthcare Conference in San Francisco, California, on January 12, 2015. The live webcast is scheduled to begin at 11:00 a.m. Pacific Time and will feature a brief overview of the company by Jay Flatley, Chief Executive Officer, followed by a question and answer session.
JPM: 62.48 (unch), ILMN: 186.22 (+2.72)
5 Crazy Habits You Might Adopt With Low-Cost Genome Sequencing
Maxx Chatsko, The Motley Fool - Motley Fool - Sun Dec 21, 11:42AM CST
The $1,000 human genome took a giant leap closer to reality when Illumina launched the HiSeq X Ten Sequencing System in early 2014. Sequencing your genome costs over five times that amount using any other system, and had cost nearly 10 times...
PACB: 7.46 (+0.01), PFE: 31.42 (-0.03), ILMN: 186.22 (+2.72), PG: 93.14 (-0.15), NVS: 93.91 (+0.66)
The Market's 10 Best Stocks
Dan Caplinger, The Motley Fool - Motley Fool - Sun Dec 21, 7:02AM CST
Source: Wikimedia Commons. Investors are always searching for the best possible stocks. That's because if you can identify a winning stock before it takes off, it can have a life-changing impact on your finances. In order to find those stocks,...
NFLX: 342.10 (+5.67), NEU: 405.00 (+5.94), MNST: 112.56 (+0.52), OPK: 9.63 (+0.21), GMCR: 137.65 (+1.10), ALXN: 181.96 (+3.09), ILMN: 186.22 (+2.72), AAPL: 112.01 (-0.53), REGN: 400.12 (+6.07), PCLN: 1,149.78 (+2.17)
Illumina Set to Possibly Pullback After Yesterday's Rally of 1.43%
Comtex SmarTrend(R) - Fri Dec 19, 3:57PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $184.67 to a high of $190.40. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $187.46 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 186.22 (+2.72)
Illumina Rises 1.43% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Dec 19, 3:57PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $184.67 to a high of $190.40. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $187.46 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ILMN: 186.22 (+2.72)
Stocks Up Big; Restoration, Accenture Hit New Highs
at Investor's Business Daily - Thu Dec 18, 10:51AM CST
Stocks were off their best levels, but held firmly higher at midday Thursday. The Nasdaq led in the stock market today, up 1.4%, while the S&P 500 and Dow Jones industrial average added 1.3%. The number of leading stocks rising in volume picked up...
RH: 96.97 (-0.16), LNKD: 231.83 (+0.34), ILMN: 186.22 (+2.72), ACN: 91.32 (-0.10)
Stocks Hold Near Highs Ahead of Fed Announcement
at Investor's Business Daily - Wed Dec 17, 12:24PM CST
Stocks held on to the majority of gains Wednesday, heading into the Federal Reserve's policy announcement. The S&P 500 was up 1.1%, while the Nasdaq gained 0.8% and the Dow added 0.9%. Volume remained below Tuesday's levels on both the Nasdaq and...
FDX: 176.42 (-0.52), RCL: 82.36 (+0.16), ILMN: 186.22 (+2.72), MCD: 93.83 (-0.39), XOM: 93.78 (-0.81), CVX: 113.47 (-0.48)
Meet 5 Big Tech Stocks Expected To See Profits Surge
at Investor's Business Daily - Tue Dec 16, 8:03PM CST
With the stock market again correcting, investors should be looking to create stock watch lists for the next uptrend. Fast-growing, large-capitalization companies are a good place to look. Today's Screen Of The Day is Big Cap Leaders, large companies...
GPRO: 66.41 (+4.87), SWKS: 74.32 (+0.92), GILD: 91.29 (+1.84), DGX: 67.94 (-0.16), AZN: 70.44 (+0.26), AMGN: 160.67 (+3.15), ILMN: 186.22 (+2.72), GM: 33.43 (-0.13), TSM: 22.35 (+0.14), NXPI: 76.75 (+0.48), COL: 86.16 (+0.28), AAPL: 112.01 (-0.53), AVGO: 100.72 (-0.06), BABA: 105.95 (+0.43)
Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 4:43PM CST
On Dec 10, 2014, we issued an updated research report on Illumina Inc. (ILMN).
BIIB: 340.89 (+5.13), AMGN: 160.67 (+3.15), ILMN: 186.22 (+2.72), AFFX: 9.80 (+0.05)
Trevena (TRVN) in Focus: Stock Rallies 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:44AM CST
Trevena, Inc. (TRVN) was a big mover last session, as the company saw its shares surge over 7% on the day.
BIIB: 340.89 (+5.13), TRVN: 5.38 (-0.37), ILMN: 186.22 (+2.72), AFFX: 9.80 (+0.05)
Stocks Stage Comeback; Leaders Still Under Pressure
at Investor's Business Daily - Mon Dec 15, 12:29PM CST
Stocks shaved the bulk of their losses Monday afternoon even though oil largely remained under pressure. The Nasdaq pared a 1.3% loss to 0.6% and the S&P 500 trimmed a 1% loss to 0.3%. Meanwhile, the Dow Jones industrial average fell 0.3%. Volume was...
RH: 96.97 (-0.16), NOAH: 20.44 (-1.00), ILMN: 186.22 (+2.72), EPAM: 48.84 (+0.33), UVE: 20.21 (+0.20)
Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021
M2 - Mon Dec 15, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/267psb/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.) to reach $19.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies Comparison of Individual Top Publicly-Held Companies to Industry Averages, 2013 - Income Statements. Balance Sheets and Cash Flow Statements Companies Mentioned - Alere Inc - Bio Rad Laboratories Inc - Cepheid - Hologic GenProbe Inc - Hologic Inc - Illumina Inc - Immucor Inc - Life Technologies Corp - PerkinElmer Inc - Promega Corp For more information visit http://www.researchandmarkets.com/research/267psb/medical Source: Plunkett Research Ltd
CPHD: 53.39 (+0.51), ILMN: 186.22 (+2.72), ALR: 37.48 (+0.37), PKI: 43.99 (-0.06), HOLX: 26.89 (+0.10)
Top Healthcare Stocks for 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 10:03AM CST
Source: Flickr user Tax Credits . This past year has been a great one for healthcare investors -- the S&P healthcare index ETF offered double the return of the S&P 500. Biotechnology stocks dominated the list of the 10 top-performing...
MNK: 97.84 (-0.29), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), AGN: 210.12 (+0.95), VRTX: 115.15 (+1.40), ALNY: 93.52 (+0.97), EW: 130.75 (+1.17), ILMN: 186.22 (+2.72), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07), PBYI: 189.96 (+0.12)
HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system
PR Newswire - Fri Dec 12, 3:29PM CST
HudsonAlpha Institute for Biotechnology today announced it has purchased the HiSeq X Ten sequencing system manufactured by Illumina, Inc. (NASDQ: ILMN). The technology will enable HudsonAlpha to produce and analyze genomic data faster and at a lower cost. The purchase stems from the Institute's commitment to research programs for genomics excellence in patient care.
ILMN: 186.22 (+2.72)
Kite Pharma (KITE) Shows Strength: Stock Moves Up 16.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:39AM CST
Kite Pharma, Inc. (KITE) was a big mover last session, as its shares rose over 16% on the day.
KITE: 51.96 (+0.45), ANIP: 55.24 (+1.79), ILMN: 186.22 (+2.72), AFFX: 9.80 (+0.05)
Celladon Corp. (CLDN) Jumps: Stock Adds 14.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 7:51AM CST
Celladon Corporation (CLDN) was a big mover last session, as its shares rose almost 15% on the day.
ANIP: 55.24 (+1.79), ILMN: 186.22 (+2.72), CLDN: 18.54 (+0.85), AFFX: 9.80 (+0.05)
SmarTrend Watching for Potential Rebound in Shares of Illumina After 1.36% Loss
Comtex SmarTrend(R) - Tue Dec 09, 4:32PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $183.65 to a high of $188.45. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $187.73 on volume of 735,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 186.22 (+2.72)